Myelosuppression (e.g., anemia, leukopenia, pancytopenia, thrombocytopenia) has been reported. Discontinuance of Linestad 600 should be considered if myelosuppression develops or worsens.
Lactic acidosis, characterized by recurrent nausea and vomiting, has been reported. Patients who develop recurrent nausea and vomiting, unexplained acidosis, or a low bicarbonate concentration while receiving linezolid should undergo immediate medical evaluation.
Peripheral and optic neuropathy, sometimes progressing to loss of vision, has been reported. If a patient experiences symptoms of visual impairment (e.g., changes in visual acuity or color vision, blurred vision, or visual field defect), an ophthalmic evaluation should be promptly performed. All patients receiving linezolid for extended periods of time (i.e., 3 months or longer) should have their visual function monitored.
Carefully medical history is necessary since CDAD has been reported to occur as late as 2 months or longer after anti-infective therapy is discontinued. If CDAD is suspected or confirmed, discontinuance of antiinfectives not directed against difficile may be needed.
A history of seizures or risk factors for seizures noted in some of these cases.
Linestad 600 should not be used during pregnancy unless clearly necessary. Breastfeeding should be discontinued prior to and throughout administration.
Patients should be warned about the potential for dizziness or symptoms of visual impairment whilst receiving Linestad 600 and should be advised not to drive or operate machinery if any of these symptoms occurs.